Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo

J. H. Peters, M. H. Ginsberg, C. M. Case, C. G. Cochrane

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This study was undertaken to determine if fibronectin containing an extra type III domain (ED1) is released during inflammatory injury of pulmonary tissue in vivo. ED1 fibronectin, measured by quantitative immunoassay, was markedly increased in bronchoalveolar lavage (BAL) fluid (2 and 4 h posttreatment) from rabbits with lung injury resulting from intrabronchial treatment with glucose oxidase to generate H2O2. This protein comprised a greater portion of total fibronectin in BAL fluid than in plasma, suggesting local release. Leukocyte-mediated lung injury after intrabronchial or intravenous treatment with phorbol myristate acetate (PMA) also affected ED1 fibronectin, triggering specific accumulation of this fibronectin variant in both BAL fluid and plasma. ED1 fibronectin in tissue fluids was largely intact and dimeric during injury, as demonstrated by Western blot analysis. Compartmental release of soluble ED1 fibronectin reflects acute pulmonary injury induced by oxidants or leukocytes in vivo.

Original languageEnglish (US)
Pages (from-to)167-174
Number of pages8
JournalAmerican Review of Respiratory Disease
Volume138
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Acute Lung Injury
Fibronectins
Oxidants
Leukocytes
Bronchoalveolar Lavage Fluid
Lung Injury
Glucose Oxidase
Tetradecanoylphorbol Acetate
Immunoassay
Western Blotting
Rabbits
Wounds and Injuries
Therapeutics
Proteins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. / Peters, J. H.; Ginsberg, M. H.; Case, C. M.; Cochrane, C. G.

In: American Review of Respiratory Disease, Vol. 138, No. 1, 1988, p. 167-174.

Research output: Contribution to journalArticle

@article{0820c150e21b42e2911137cfb9aceffb,
title = "Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo",
abstract = "This study was undertaken to determine if fibronectin containing an extra type III domain (ED1) is released during inflammatory injury of pulmonary tissue in vivo. ED1 fibronectin, measured by quantitative immunoassay, was markedly increased in bronchoalveolar lavage (BAL) fluid (2 and 4 h posttreatment) from rabbits with lung injury resulting from intrabronchial treatment with glucose oxidase to generate H2O2. This protein comprised a greater portion of total fibronectin in BAL fluid than in plasma, suggesting local release. Leukocyte-mediated lung injury after intrabronchial or intravenous treatment with phorbol myristate acetate (PMA) also affected ED1 fibronectin, triggering specific accumulation of this fibronectin variant in both BAL fluid and plasma. ED1 fibronectin in tissue fluids was largely intact and dimeric during injury, as demonstrated by Western blot analysis. Compartmental release of soluble ED1 fibronectin reflects acute pulmonary injury induced by oxidants or leukocytes in vivo.",
author = "Peters, {J. H.} and Ginsberg, {M. H.} and Case, {C. M.} and Cochrane, {C. G.}",
year = "1988",
language = "English (US)",
volume = "138",
pages = "167--174",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo

AU - Peters, J. H.

AU - Ginsberg, M. H.

AU - Case, C. M.

AU - Cochrane, C. G.

PY - 1988

Y1 - 1988

N2 - This study was undertaken to determine if fibronectin containing an extra type III domain (ED1) is released during inflammatory injury of pulmonary tissue in vivo. ED1 fibronectin, measured by quantitative immunoassay, was markedly increased in bronchoalveolar lavage (BAL) fluid (2 and 4 h posttreatment) from rabbits with lung injury resulting from intrabronchial treatment with glucose oxidase to generate H2O2. This protein comprised a greater portion of total fibronectin in BAL fluid than in plasma, suggesting local release. Leukocyte-mediated lung injury after intrabronchial or intravenous treatment with phorbol myristate acetate (PMA) also affected ED1 fibronectin, triggering specific accumulation of this fibronectin variant in both BAL fluid and plasma. ED1 fibronectin in tissue fluids was largely intact and dimeric during injury, as demonstrated by Western blot analysis. Compartmental release of soluble ED1 fibronectin reflects acute pulmonary injury induced by oxidants or leukocytes in vivo.

AB - This study was undertaken to determine if fibronectin containing an extra type III domain (ED1) is released during inflammatory injury of pulmonary tissue in vivo. ED1 fibronectin, measured by quantitative immunoassay, was markedly increased in bronchoalveolar lavage (BAL) fluid (2 and 4 h posttreatment) from rabbits with lung injury resulting from intrabronchial treatment with glucose oxidase to generate H2O2. This protein comprised a greater portion of total fibronectin in BAL fluid than in plasma, suggesting local release. Leukocyte-mediated lung injury after intrabronchial or intravenous treatment with phorbol myristate acetate (PMA) also affected ED1 fibronectin, triggering specific accumulation of this fibronectin variant in both BAL fluid and plasma. ED1 fibronectin in tissue fluids was largely intact and dimeric during injury, as demonstrated by Western blot analysis. Compartmental release of soluble ED1 fibronectin reflects acute pulmonary injury induced by oxidants or leukocytes in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0023684250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023684250&partnerID=8YFLogxK

M3 - Article

C2 - 3202394

AN - SCOPUS:0023684250

VL - 138

SP - 167

EP - 174

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -